KEAP1 inhibitors like pentoxifylline and pirfenidone improve the antioxidant capacity and reduce COVID-19 severity in patients with ALI/ARDS (Chavarría et al. 2021; Hamidi et al. 2021). This evidence concerns the gene KEAP1 and acute respiratory distress syndrome.